Prescription drug shortages in the United States declined by 23% in 2025, marking the most significant annual improvement in over ten years according to new data from the American Society of Health-System Pharmacists. The number of reported shortages fell from 420 in 2024 to 323 in 2025, signaling progress in pharmaceutical supply stabilization.
However, the analysis reveals troubling underlying issues that threaten continued improvement. Cancer medications and generic injectable drugs remain disproportionately affected, with oncology drugs comprising 28% of all shortages. More concerning, the average duration of drug shortages has increased to 18 months, indicating that supply chain disruptions, when they occur, persist longer and impact patient care more severely.
Experts attribute ongoing challenges to manufacturing quality issues and structural vulnerabilities in pharmaceutical production networks. While the overall decline offers cautious optimism, healthcare systems must remain vigilant as systemic problems continue to threaten access to critical medications.
Read the full article on GMJ Newsroom.
Was this article helpful?
GMJ Brief · Announcement
📰 Read the full article: Drug Shortages Decline 23% in US, But Systemic Problems Persist →
